NCT04317963View on ClinicalTrials.gov

Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection

CompletedOBSERVATIONAL

Enrollment

180

Participants

Timeline

Start Date

February 12, 2020

Primary Completion Date

February 22, 2023

Study Completion Date

February 22, 2023

Conditions

Clostridium Difficile InfectionClostridium Difficile Infection Recurrence

Interventions

BIOLOGICAL

Bezlotoxumab

Bezlotoxumab 10 mg/kg IV infusion in addition to standard CDI treatment

DRUG

Standard CDI treatment

Standard CDI treatment includes one or a combination of oral vancomycin, oral vancomycin taper and/or pulse, fidaxomicin, and fidaxomicin taper and/or pulse

Trial Locations (1)

60153

Loyola University Medical Center, Maywood

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Illinois at Chicago

OTHER

NCT04317963 - Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection | Biotech Hunter | Biotech Hunter